866-997-4948(US-Canada Toll Free)

Bydureon (Type 2 Diabetes) Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Diabetes

No. of Pages : 44 Pages


GlobalDatas pharmaceuticals report, Bydureon (Type 2 Diabetes) Analysis and Forecasts to 2020 provides Bydureon sales estimates for US, Eu5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2011-2020). The report also includes information onType 2 Diabetes market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Bydureon
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Bydureon including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecast for 2011-2020 for Bydureon in the US, EU5 and japan

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 5
2.1 Diabetes 5
2.2 Epidemiology 5
2.2.1 Prevalence 5
2.2.2 Mortality 7
2.3 Etiology and Risk Factors 9
2.3.1 Obesity 9
2.3.2 Sedentary Lifestyle 9
2.3.3 Family History and Genetics 9
2.3.4 Ethnicity 9
2.3.5 Old Age 9
2.4 Economic Impact of Diabetes 9
2.5 GlobalData Report Guidance 11

3 Type 2 Diabetes: Market Characterization 12
3.1 Type 2 Diabetes Market 12
3.2 Type 2 Diabetes Market Forecasts 13
3.3 Type 2 Diabetes Market: Drivers and Restraints 14
3.3.1 Drivers 14
3.3.2 Restraints 15

4 Classification of Diabetes 16
4.1 Types of Diabetes 16
4.1.1 Type 1 Diabetes 16
4.1.2 Type 2 Diabetes 16
4.1.3 Gestational Diabetes 16
4.2 Diabetes Complications 16
4.2.1 Cardiovascular Disease 16
4.2.2 Nephropathy 17
4.2.3 Neuropathy 17
4.2.4 Amputation 17
4.2.5 Retinopathy 17

5 Evolution of Anti-Diabetic Treatments 18

6 Medications 20

6.1 Insulin 20
6.2 Oral Medications 20
6.2.1 Sulfonylureas (SUR) 20
6.2.2 Biguanides (BGDs) 20
6.2.3 Alpha-Glucosidase Inhibitors (AGI) 22
6.2.4 Meglitinides 22
6.2.5 Thiazolidinediones (TZDs) 23
6.2.6 Dipeptidyl Peptidase IV (DPP- 4) Inhibitors 24
6.2.7 Oral Combination Therapy 24
6.3 Other Injectionable Medications 25
6.3.1 Pramlintide 25
6.3.2 Exenatide 25
6.4 Market Share as per Classes in Type 2 Diabetes 25

7 Bydureon 26
7.1 Introduction 26
7.2 Mechanism of Action 26
7.3 Clinical Studies 26
7.3.1 DURATION-1 27
7.3.2 DURATION-4 27
7.4 Approval Status of Bydureon 28
7.4.1 In the US 28
7.4.2 In EU 28
7.5 Factors Affecting Sales of Bydureon 28
7.5.1 Once Weekly Dosage 28
7.5.2 Association of Bydureon with Weight Loss among Patients 28
7.5.3 Potential Relationship to Acute Pancreatitis 28
7.5.4 Lower Efficacy of Bydureon When Compared with Victoza 28
7.5.5 Late Approval of Bydureon 29
7.6 Drug Evaluation 29
7.6.1 Drug Risk Benefit Score 29
7.6.2 Intensity of Competition 30
7.7 Sales Forecasts 30
7.7.1 Target Patient Pool for Bydureon 30
7.7.2 Dosing 30
7.7.3 Market Penetration 30
7.7.4 Annual Cost of Therapy 31
7.7.5 Sales Projections of Bydureon 32

8 Diabetes Market: Appendix 41
8.1 Market Definitions 41
8.2 List of Abberiviations 41
8.3 Research Methodology 41
8.3.1 Coverage 41
8.3.2 Secondary Research 42
8.3.3 Forecasting 42
8.3.4 Net Penetration of Drug 42
8.3.5 Net Annual Dosing 43
8.3.6 Annual Cost of Therapy 43
8.3.7 Primary Research 43
8.3.8 Expert Panels 43
8.4 Drug Sales Estimates Model 44
8.5 Contact Us 44
8.6 Disclaimer 44
8.7 Sources 44

List of Table


Table 1: Diabetes, World, Prevalence Estimates for the age group 20-79 years (million), 2000-2030 5
Table 2: Diabetes, Top 10 Countries, by Prevalence (million), 2010 and 2030 7
Table 3: Diabetes, Top 10 Countries, Highest Health Expenditures ($bn), 2010 10
Table 4: Type 2 Diabetes, World, Major Marketed Drugs, 2010 12
Table 5: Type 2 Diabetes, World, Major Pipeline Products in Phase III 13
Table 6: Diabetes, Worldwide, Prevalence Estimates, 2010 and 2030 14
Table 7: Overweight*, Global, Prevalence Estimates in Males Aged 15 and above (%), 2005 15
Table 8: Diabetes Drugs Evolution 18
Table 9: DURATION-1 Study Results 26
Table 10: DURATION-4 Study Results 26
Table 11: Drug Risk Benefit Score of Bydureon 28
Table 12: Annual Cost of Therapy of Bydureon, 2011 30
Table 13: Bydureon, Type 2 Diabetes, Global, Sales Forecasts ($m), 20112020 31
Table 14: Bydureon, Type 2 Diabetes, The US, Sales Forecasts ($m), 20122020 32
Table 15: Bydureon, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20112020 33
Table 16: Bydureon, Type 2 Diabetes, France, Sales Forecasts ($m), 20122020 34
Table 17: Bydureon, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20112020 35
Table 18: Bydureon, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 36
Table 19: Bydureon, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20122020 37
Table 20: Bydureon, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20122020 38

List of Chart


Figure 1: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2010 6
Figure 2: Diabetes, World, Comparative Prevalence in Age Group 20-79 years (%), 2030 6
Figure 3: Diabetes, World, Mortality, 2010 7
Figure 4: Top 10 Causes of Mortality, Worldwide, 2008 8
Figure 5: Type 2 Diabetes, Global, Market Size Forecasts ($bn), 20102020 13
Figure 6: Mechanism of Action of Sulfonylurea 19
Figure 7: Mechanism of Action of Biguanide, Thiazolidinediones, Alpha-Glucosidase Inhibitors 20
Figure 8: Mechanism of Action of Metformin and Alpha-Glucosidase Inhibitors 21
Figure 9: Mechanism of Action of Thiazolidinediones 22
Figure 10: Mechanism of Action of DPP IV Inhibitors 23
Figure 11: Type 2 Diabetes, Global, Market Share by Value, By Class (%), 2010 24
Figure 12: Bydureon, Diabetes, Global, Sales Forecasts ($m), 20112020 31
Figure 13: Bydureon, Type 2 Diabetes, The US, Sales Forecasts ($m), 20122020 32
Figure 14: Bydureon, Type 2 Diabetes, The UK, Sales Forecasts ($m), 20112020 33
Figure 15: Bydureon, Type 2 Diabetes, France, Sales Forecasts ($m), 20122020 34
Figure 16: Bydureon, Type 2 Diabetes, Germany, Sales Forecasts ($m), 20112020 35
Figure 17: Bydureon, Type 2 Diabetes, Italy, Sales Forecasts ($m), 20122020 36
Figure 18: Bydureon, Type 2 Diabetes, Spain, Sales Forecasts ($m), 20122020 37
Figure 19: Bydureon, Type 2 Diabetes, Japan, Sales Forecasts ($m), 20122020 38
Figure 20: Bydureon, Type 2 Diabetes, Global, Sales Distribution (%), 2020 39

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *